Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPT-HN: Amivantamab, Carboplatin and Paclitaxel in Head and Neck Cancer
NCT07062354Phase 2Enrolling by invitation
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2026
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab hyaluronidase in head and neck squamous cell carcinoma (HNSCC), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Response Rate up to 2 years. Started Mar 2026; status: enrolling by invitation.
02
Drugs
amivantamab hyaluronidase
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07062354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062354.